A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
Latest Information Update: 15 Feb 2024
At a glance
- Drugs Mefloquine (Primary) ; Memantine (Primary) ; Metformin (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 08 Feb 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
- 08 Feb 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Sep 2025.
- 07 Feb 2024 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.